Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob van Oosten

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 2, 2019
Emerging safety issues in alemtuzumab-treated MS patientsJoep Killestein, Bob van Oosten
Brain Research|August 22, 2017
Time is vision in recurrent optic neuritisEsther Osinga, Bob van Oosten, Willemien de Vries-Knoppert, et al.
Neuroradiology|March 28, 2020
Response: Brain miliary enhancementJoseph C J Bot, Linda Mazzai, Rogier E Hagenbeek, et al.
Neuroradiology|January 12, 2020
Brain miliary enhancementJoseph C J Bot, Linda Mazzai, Rogier E Hagenbeek, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Whipple's disease in mentally retarded patients: report of two casesAnnika Pettersson, Lisa van Winsen, Bob van Oosten, et al.
The American Journal of Emergency Medicine|December 10, 2023
Successful treatment of respiratory failure in Hirayama diseaseNik Sol, Joost Hartman, Mara Ten Kate, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 2, 2019
Emerging safety issues in alemtuzumab-treated MS patientsJoep Killestein, Bob van Oosten
Brain Research|August 22, 2017
Time is vision in recurrent optic neuritisEsther Osinga, Bob van Oosten, Willemien de Vries-Knoppert, et al.
Neuroradiology|March 28, 2020
Response: Brain miliary enhancementJoseph C J Bot, Linda Mazzai, Rogier E Hagenbeek, et al.
Neuroradiology|January 12, 2020
Brain miliary enhancementJoseph C J Bot, Linda Mazzai, Rogier E Hagenbeek, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Whipple's disease in mentally retarded patients: report of two casesAnnika Pettersson, Lisa van Winsen, Bob van Oosten, et al.
The American Journal of Emergency Medicine|December 10, 2023
Successful treatment of respiratory failure in Hirayama diseaseNik Sol, Joost Hartman, Mara Ten Kate, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Pageof 1